Table 5.
Multiorgan ECV Response to Treatment 24 Months After Initiating Chemotherapy, Compared With the Hematologic Response and Repeat SAP Scintigraphy at 24 Months
| All Patients Who Had Repeat CMR With ECV Mapping at 24 mo (N = 107, Liver ECV Measurable in 95 Patients and Spleen Measurable in 94 Patients) | ||||
|---|---|---|---|---|
| Hematologic Response | Complete Response (n = 55, 51.4%) | Very Good Partial Response (n = 31, 29.0%) | Partial Response (n = 17, 15.0%) | No Response (n = 4, 3.7%) |
| Liver ECV regression | 14 | 3 | 0 | 0 |
| Spleen ECV regression | 8 | 6 | 1 | 0 |
| Cardiac ECV regression | 30 | 11 | 0 | 0 |
| Stable liver ECV | 33 | 23 | 11 | 3 |
| Stable spleen ECV | 41 | 22 | 12 | 2 |
| Stable cardiac ECV | 24 | 18 | 8 | 2 |
| Liver ECV progression | 1 | 3 | 4 | 0 |
| Spleen ECV progression | 0 | 1 | 1 | 0 |
| Cardiac ECV progression | 1 | 2 | 9 | 2 |
| Patients With Repeat SAP Scintigraphy and CMR With ECV Mapping at 24 mo (N = 64, Liver ECV Measurable in 61 and Spleen Measurable in 58) | |||
|---|---|---|---|
| Liver Response | Liver Regression on SAP (n = 2) | Stable Liver on SAP (n = 56) | Liver Progression on SAP (n = 3) |
| Liver ECV regression | 2 | 8 | 0 |
| Stable liver ECV | 0 | 46 | 1 |
| Liver ECV progression | 0 | 2 | 2 |
| Spleen Response | Spleen Regression on SAP Scintigraphy (n = 15) | Stable Spleen on SAP Scintigraphy (n = 42) | Spleen Progression on SAP Scintigraphy (n = 1) |
|---|---|---|---|
| Spleen ECV regression | 8 | 6 | 0 |
| Stable spleen ECV | 7 | 34 | 0 |
| Spleen ECV progression | 0 | 2 | 1 |